Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.
Also called NCT01941836
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 349 participants
- Registry
-
NCT01941836
-
- Other papers using this trial's data
- Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01941836. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- ETC-1002
- Intervention (Drug)
- Ezetimibe
- Lead sponsor
- Esperion Therapeutics, Inc.
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct01941836- Content hash
45a13c73853d43539ea14773049c2acaafbbb9c7a53f1396ef234ddacecadcee